President Joe Biden (Susan Walsh/AP Images)
December 14, 2023 07:04 AM EST
Pharma
FDA+
Law

White House keeps fo­cus on low­er­ing drug prices, turns Re­gen­eron's con­tract lan­guage in­to new stan­dard

Zachary Brennan

Senior Editor

As Pres­i­dent Joe Biden strug­gles in the most re­cent 2024 gen­er­al elec­tion polls, the White House is keep­ing its fo­cus on drug prices, go­ing af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times